Home » News » Clinical Intelligence » Unigene accelerates anorexigenic peptide

Unigene accelerates anorexigenic peptide

Monday, March 7, 2011

Unigene Laboratories said its lead proprietary anorexigenic peptide, UGP281, is progressing. An anorexigenic peptide diminishes or controls appetite and offers potential therapeutic benefit to morbidly obese patients. The company will file an Investigational New Drug (IND) application with the FDA and initiate phase I clinical studies in 2012.

UGP281 has demonstrated substantial decreases in food consumption and weight in in vivo preclinical studies. Unigene’s “Peptelligence” core competence will allow UGP281 to be manufactured and delivered via a proprietary recombinant production and oral delivery technologies. Longer-term oral studies with UGP281 in dog models are currently ongoing.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!